Immunome Inc., a biotechnology company specializing in targeted cancer therapies, has announced the approval of inducement awards for 13 new employees under its 2024 Inducement Plan. The Compensation Committee of the Board of Directors has granted non-statutory stock options to purchase a total of 173,000 shares of common stock. These stock options have an exercise price of $9.06 per share, based on the closing sales price on June 2, 2025. The options will vest over four years: 25% on the first anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, contingent upon the employees' ongoing service with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605838138) on June 05, 2025, and is solely responsible for the information contained therein.